(9 beta,13 alpha,14 beta, 20 alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic acid methyl ester, celastrol methyl ester, pristimerin
Name | Pristimerin | ||
PubChem CID | 159516 | ||
Molecular Weight | 464.6g/mol | ||
Synonyms |
(9 beta,13 alpha,14 beta, 20 alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic acid methyl ester, celastrol methyl ester, pristimerin |
||
Formula | C₃₀H₄₀O₄ | ||
SMILES | CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)OC)C)C)C)C)O | ||
InChI | 1S/C30H40O4/c1-18-19-8-9-22-28(4,20(19)16-21(31)24(18)32)13-15-30(6)23-17-27(3,25(33)34-7)11-10-26(23,2)12-14-29(22,30)5/h8-9,16,23,32H,10-15,17H2,1-7H3/t23-,26-,27-,28+,29-,30+/m1/s1 | ||
InChIKey | JFACETXYABVHFD-WXPPGMDDSA-N | ||
CAS Number | 1258-84-0 | ||
ChEMBL ID | CHEMBL54804 | ||
ChEBI ID | CHEBI:8416 | ||
Herb ID | HBIN040737 | ||
Drug Bank ID | DB17049 | ||
KEGG ID | C08633 | ||
Toxicity | Organism | Test Type | Route(Dose) |
rat | LD50 | intraperitoneal(165 mg/kg) | |
mouse | LD50 | intraperitoneal(254 mg/kg) | |
rat | LD50 | oral(322 mg/kg) | |
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | NanSheTeng | ||
Use Part | Stem Vine | ||
Habitat | China | ||
Flavor | Bitter, Pungent | ||
Meridian Tropism | Liver, Bladder | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Celastrales
-->Family: Celastraceae
-->Genus: Celastrus
-->Species: Celastrus orbiculatus
|
Chineses Pinyin | QiaoCha | ||
Use Part | Leaf | ||
Habitat | HaiNan, GuangXi | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Celastrales
-->Family: Celastraceae
-->Genus: Catha
-->Species: Catha edulis
|
Chineses Pinyin | BianShuoTeng | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Celastrales
-->Family: Celastraceae
-->Genus: Pristimera
-->Species: Pristimera indica
|
Pair Name | Pristimerin, Sorafenib | |||
Partner Name | Sorafenib | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Inhibition-->Cell migration and angiogenesis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP4 | hsa837 | |
Up-regulation | Expression | CYCS | hsa54205 | |
Up-regulation | Expression | DDIT3 | hsa1649 | |
Up-regulation | Phosphorylation | EIF2AK3 | hsa9451 | |
Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
Up-regulation | Expression | FOXO1 | hsa2308 | |
Up-regulation | Expression | HSPA5 | hsa3309 | |
Up-regulation | Expression | PSMD9 | hsa5715 | |
In Vitro Model | CRHCs | CRHCs isolated from the 9 patients would be used for the following experiments. | Homo sapiens (Human) | N.A. |
Result | Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway |
Pair Name | Pristimerin, Paclitaxel | |||
Partner Name | Paclitaxel | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Gene Regulation | Up-regulation | Expression | CDH1 | hsa999 |
Down-regulation | Expression | CDH2 | hsa1000 | |
Down-regulation | Expression | VIM | hsa7431 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
In Vivo Model | Xenograft inhibition of P@FPP NMs The A549 xenograft bearing nude mice (~ 80 mm3) were randomly divided into five groups (n = 4) and then intravenously injection of the following formulations: PBS, PRI, PTX, PRI in combination of PTX, and P@FPP NMs. | |||
Result | This active-targeting NMs provides a versatile nano-herb strategy for improving tumor-targeting of Chinese herbal extracts, which may help in the promotion of enhancing chemosensitivity of NSCLC in clinical applications. |
Pair Name | Pristimerin, Gemcitabine | |||
Partner Name | Gemcitabine | |||
Disease Info | [ICD-11: 2C10.0] | Pancreatic ductal adenocarcinoma | Investigative | |
Biological Phenomena | Induction-->DNA damage | |||
Gene Regulation | Down-regulation | Phosphorylation | CHEK1 | hsa1111 |
Down-regulation | Expression | TP53 | hsa7157 | |
In Vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0152 |
BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 | |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
Result | These results show that pristimerin acts as a naturally occurring inhibitor of RSR, and a novel therapeutic strategy of combining pristimerin and gemcitabine deserves further detailed investigation in PC models in vivo. |
No. | Title | Href |
---|---|---|
1 | Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. Phytomedicine. 2021 Jun;86:153563. doi: 10.1016/j.phymed.2021.153563. | Click |
2 | Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy. Nano Converg. 2022 Nov 24;9(1):52. doi: 10.1186/s40580-022-00343-5. | Click |
3 | Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. Food Chem Toxicol. 2021 Jan;147:111919. doi: 10.1016/j.fct.2020.111919. | Click |